Trial Profile
Efficacy and safety of transcatheter arterial chemoembolization using combination of epirubicin and miriplatin for hepatocellular carcinoma -Prospective comparative study with transcatheter arterial chemoembolization using epirubicin-
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs Epirubicin (Primary) ; Miriplatin (Primary) ; Ethiodized oil
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- 27 Nov 2012 New trial record
- 19 Oct 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.